The bacterial ghost platform system

References

• Hutchinson CA III, Sinsheimer RL. The process of infection with bacteriophage phiX174. X. Mutations in a phiX174 lysis gene. J Mol Biol 1966; 18:429 - 447
   PubMed Web of Science ®Google Scholar
• Henrich B, Lubitz W, Plapp R. Lysis of Escherichia coli by induction of cloned phiX174 genes. Mol Gen Genet 1982; 185:493 - 497
   PubMedGoogle Scholar
• Young KD, Young R. Lytic action of cloned phiX174 gene E. J Virol 1982; 44:993 - 1002
   PubMed Web of Science ®Google Scholar
• Barrell BG, Air GM, Hutchison CA 3rd. Overlapping genes in bacteriophage phiX174. Nature 1976; 264:34 - 41
   PubMed Web of Science ®Google Scholar
• Pollock TJ, Tessman ES, Tessman I. Identification of lysis protein E of bacteriophage phiX174. J Virol 1978; 28:408 - 410
   PubMed Web of Science ®Google Scholar
• Denhardt DT, Sinsheimer RL. The process of infection with bacteriophage phi-X174. 3. Phage maturation and lysis after synchronized infection. J Mol Biol 1965; 12:641 - 646
   PubMed Web of Science ®Google Scholar
• Markert A, Zillig W. Studies on the lysis of Escherichia coli C by bacteriophage PhiX174. Virology 1965; 25:88 - 97
   PubMed Web of Science ®Google Scholar
• Bläsi U, Linke RP, Lubitz W. Evidence for membrane-bound oligomerization of bacteriophage phiX174 lysis protein-E. J Biol Chem 1989; 264:4552 - 4558
   PubMed Web of Science ®Google Scholar
• Witte A, Lubitz W. Biochemical characterization of phiX174-protein-E-mediated lysis of Escherichia coli. Eur J Biochem 1989; 180:393 - 398
   PubMedGoogle Scholar
• Bläsi U, Geisen R, Lubitz W, Henrich B, Plapp R. Localisation of the bacteriophage phiX174 lysis gene product in the cell envelope of Escherichia coli 1983; Berlin & New York de Gruyter
   Google Scholar
• Halfmann G, Leduc M, Lubitz W. Different sensitivity of autolytic deficient Escherichia coli mutants to the mode of induction. FEMS Microbiology Letters 1984; 24:205 - 208
   Web of Science ®Google Scholar
• Halfmann G, Lubitz W. Differential induction of Escherichia coli autolysis by penicillin and the bacteriophage phi X174 gene E product. J Bacteriol 1986; 166:683 - 685
   PubMed Web of Science ®Google Scholar
• Lubitz W, Pugsley AP. Changes in host cell phospholipid composition of phiX174 gene E product. FEMS Microbiology Letters 1985; 30:171 - 175
   Web of Science ®Google Scholar
• Bayer ME. Areas of adhesion between wall and membrane of Escherichia coli. J Gen Microbiol 1968; 53:395 - 404
   PubMedGoogle Scholar
• Witte A, Lubitz W, Bakker EP. Proton-motive-force-dependent step in the pathway to lysis of Escherichia coli induced by bacteriophage phi X174 gene E product. J Bacteriol 1987; 169:1750 - 1752
   PubMed Web of Science ®Google Scholar
• Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W. Endogenous transmembrane tunnel formation mediated by phiX174 lysis protein E. J Bacteriol 1990; 172:4109 - 4114
   PubMed Web of Science ®Google Scholar
• Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of phiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 1992; 157:381 - 388
   PubMed Web of Science ®Google Scholar
• Bläsi U, Henrich B, Lubitz W. Lysis of Escherichia coli by cloned phiX174 gene E depends on its expression. J Gen Microbiol 1985; 131:1107 - 1114
   PubMedGoogle Scholar
• Lubitz W, Halfmann G, Plapp R. Lysis of Escherichia coli after infection with phiX174 depends on the regulation of the cellular autolytic system. J Gen Microbiol 1984; 130:1079 - 1087
   PubMedGoogle Scholar
• Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W. Mutations in cell division proteins FtsZ and FtsA inhibit phiX174 protein-E-mediated lysis of Escherichia coli. Arch Microbiol 1998; 170:259 - 268
   PubMed Web of Science ®Google Scholar
• Witte A, Wanner G, Lubitz W, Holtje JV. Effect of phi X174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol Lett 1998; 164:149 - 157
   PubMed Web of Science ®Google Scholar
• Bernhardt TG, Roof WD, Young R. Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis. Proc Natl Acad Sci USA 2000; 97:4297 - 4302
   PubMed Web of Science ®Google Scholar
• Schön P, Schrot G, Wanner G, Lubitz W, Witte A. Two-stage model for integration of the lysis protein E of phiX174 into the cell envelope of Escherichia coli. FEMS Microbiol Rev 1995; 17:207 - 212
   PubMed Web of Science ®Google Scholar
• Jalava K, Hensel A, Szostak M, Resch S, Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J Control Release 2002; 85:17 - 25
   PubMed Web of Science ®Google Scholar
• Lubitz W, Witte A, Eko FO, Kamal M, Jechlinger W, Brand E, et al. Extended recombinant bacterial ghost system. J Biotechnol 1999; 73:261 - 273
   PubMed Web of Science ®Google Scholar
• Halfmann G, Gotz F, Lubitz W. Expression of bacteriophage PhiX174 lysis gene E in Staphylococcus carnosus TM300. FEMS Microbiol Lett 1993; 108:139 - 143
   PubMed Web of Science ®Google Scholar
• Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2003; 2:45 - 51
   PubMedGoogle Scholar
• Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine 2009; Austin Landes Bioscience
   Google Scholar
• Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev Vaccines 2007; 6:241 - 253
   PubMed Web of Science ®Google Scholar
• Szostak M, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles 1991; New York Cold Spring Harbor Laboratory Press
   Google Scholar
• Szostak M, Wanner G, Lubitz W. Recombinant bacterial ghosts as vaccines. Res Microbiol 1990; 141:1005 - 1007
   PubMed Web of Science ®Google Scholar
• Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 2004; 172:6858 - 6865
   PubMed Web of Science ®Google Scholar
• Mayr UB, Koller VJ, Lubitz P, Lubitz W. Sleator R, Hill C. Bacterial ghosts as vaccine and drug delivery platforms. Patho-Biotechnology 2008; Austin, TX Landes Bioscience 50 - 59
   Google Scholar
• Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev 2005; 57:1381 - 1391
   PubMed Web of Science ®Google Scholar
• Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 2006; 3:11 - 22
   PubMedGoogle Scholar
• Walcher P, Mayr UB, Azimpour-Tabrizi C, Eko FO, Jechlinger W, Mayrhofer P, et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev Vaccines 2004; 3:681 - 691
   PubMedGoogle Scholar
• Jechlinger W, Glocker J, Haidinger W, Matis A, Szostak MP, Lubitz W. Modulation of gene expression by promoter mutants of the lambdacI857/pRM/pR system. J Biotechnol 2005; 116:11 - 20
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Szostak MP, Witte A, Lubitz W. Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol Lett 1999; 173:347 - 352
   PubMed Web of Science ®Google Scholar
• Haidinger W, Szostak MP, Jechlinger W, Lubitz W. Online monitoring of Escherichia coli ghost production. Appl Environ Microbiol 2003; 69:468 - 474
   PubMed Web of Science ®Google Scholar
• Haidinger W, Szostak MP, Beisker W, Lubitz W. Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS. Cytometry 2001; 44:106 - 112
   PubMedGoogle Scholar
• Haidinger W, Mayr UB, Szostak MP, Resch S, Lubitz W. Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease. Appl Environ Microbiol 2003; 69:6106 - 6113
   PubMed Web of Science ®Google Scholar
• Perrin P, Morgeaux S. Inactivation of DNA by beta-propiolactone. Biologicals 1995; 23:207 - 211
   PubMed Web of Science ®Google Scholar
• Hensel A, van Leengoed LA, Szostak M, Windt H, Weissenbock H, Stockhofe-Zurwieden N, et al. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J Biotechnol 1996; 44:171 - 181
   PubMed Web of Science ®Google Scholar
• Hensel A, Stockhofe-Zurwieden N, Petzoldt K, Lubitz W. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infect Immun 1995; 63:3048 - 3053
   PubMed Web of Science ®Google Scholar
• Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J Biotechnol 2000; 83:161 - 172
   PubMed Web of Science ®Google Scholar
• Hensel A, Huter V, Katinger A, Raza P, Strnistschie C, Roesler U, et al. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 2000; 18:2945 - 2955
   PubMed Web of Science ®Google Scholar
• Marchart J, Dropmann G, Lechleitner S, Schlapp T, Wanner G, Szostak MP, et al. Pasteurella multocida and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 2003; 21:3988 - 3997
   PubMed Web of Science ®Google Scholar
• Marchart J, Rehagen M, Dropmann G, Szostak MP, Alldinger S, Lechleitner S, et al. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 2003; 21:1415 - 1422
   PubMed Web of Science ®Google Scholar
• Eko FO, Schukovskaya T, Lotzmanova EY, Firstova VV, Emalyanova NV, Klueva SN, et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003; 21:3663 - 3674
   PubMed Web of Science ®Google Scholar
• Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane. Dev Biol Stand 1995; 84:255 - 262
   PubMedGoogle Scholar
• Huter V, Szostak MP, Gampfer J, Prethaler S, Wanner G, Gabor F, et al. Bacterial ghosts as drug carrier and targeting vehicles. J Control Release 1999; 61:51 - 63
   PubMed Web of Science ®Google Scholar
• Kennedy EP. Osmotic regulation and the biosynthesis of membrane-derived oligosaccharides in Escherichia coli. Proc Natl Acad Sci USA 1982; 79:1092 - 1095
   PubMed Web of Science ®Google Scholar
• Kuen B, Sara M, Lubitz W. Heterologous expression and self-assembly of the S-layer protein SbsA of Bacillus stearothermophilus in Escherichia coli. Mol Microbiol 1996; 19:495 - 503
   PubMed Web of Science ®Google Scholar
• Truppe M, Howorka S, Schroll G, Lechleitner S, Kuen B, Resch S, et al. Biotechnological applications of recombinant S-layer proteins rSbsA and rSbsB from Bacillus stearothermophilus PV72. FEMS Microbiol Rev 1997; 20:88 - 98
   Google Scholar
• Howorka S, Sara M, Wang Y, Kuen B, Sleytr UB, Lubitz W, et al. Surface-accessible residues in the monomeric and assembled forms of a bacterial surface layer protein. J Biol Chem 2000; 275:37876 - 37886
   PubMed Web of Science ®Google Scholar
• Riedmann EM, Kyd JM, Smith AM, Gomez-Gallego S, Jalava K, Cripps AW, et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts—a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol Med Microbiol 2003; 37:185 - 192
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release 2004; 94:63 - 74
   PubMed Web of Science ®Google Scholar
• Paukner S, Kohl G, Jalava K, Lubitz W. Sealed bacterial ghosts—novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target 2003; 11:151 - 161
   PubMed Web of Science ®Google Scholar
• Hatfaludi T, Liska M, Zellinger D, Ousman JP, Szostak M, Ambrus A, et al. Bacterial ghost technology for pesticide delivery. J Agric Food Chem 2004; 52:5627 - 5634
   PubMed Web of Science ®Google Scholar
• Gentschev I, Dietrich G, Spreng S, Kolb-Maurer A, Brinkmann V, Grode L, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 2001; 19:2621 - 2628
   PubMed Web of Science ®Google Scholar
• Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006; 103:14453 - 14458
   PubMed Web of Science ®Google Scholar
• Medina E, Guzman CA. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001; 19:1573 - 1580
   PubMed Web of Science ®Google Scholar
• Mengesha A, Dubois L, Chiu RK, Paesmans K, Wouters BG, Lambin P, et al. Potential and limitations of bacterial-mediated cancer therapy. Front Biosci 2007; 12:3880 - 3891
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Tsuji T, Jager E, Briones G, Ritter G, Old LJ, et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008; 111:1404 - 1412
   PubMed Web of Science ®Google Scholar
• Reschel T, Konak C, Oupicky D, Seymour LW, Ulbrich K. Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations. J Control Release 2002; 81:201 - 217
   PubMed Web of Science ®Google Scholar
• Schnell S, Young JW, Houghton AN, Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol 2000; 164:1243 - 1250
   PubMed Web of Science ®Google Scholar
• Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004; 27:191 - 200
   PubMed Web of Science ®Google Scholar
• Weiner DB. Introduction to DNA vaccines issue. Vaccine 2006; 24:4459 - 4460
   PubMed Web of Science ®Google Scholar
• Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006; 17:1051 - 1061
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26:373 - 380
   PubMed Web of Science ®Google Scholar
• Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol Ther 2005; 11:215 - 223
   PubMed Web of Science ®Google Scholar
• Lubitz W. Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther 2001; 1:765 - 771
   PubMed Web of Science ®Google Scholar
• Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett 2007;
   PubMed Web of Science ®Google Scholar
• Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005; 28:136 - 143
   PubMed Web of Science ®Google Scholar
• Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett 2008; 262:54 - 63
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003; 299:1400 - 1403
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23:975 - 1028
   PubMed Web of Science ®Google Scholar
• Mayrhofer P, Tabrizi CA, Walcher P, Haidinger W, Jechlinger W, Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J Control Release 2005; 102:725 - 735
   PubMed Web of Science ®Google Scholar
• Jechlinger W, Azimpour Tabrizi C, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 2004; 8:222 - 231
   PubMed Web of Science ®Google Scholar
• Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16:126 - 131
   PubMed Web of Science ®Google Scholar
• Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54:3 - 20
   PubMed Web of Science ®Google Scholar
• Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1:363 - 369
   PubMedGoogle Scholar
• Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunol Immunother 2006; 55:119 - 130
   PubMed Web of Science ®Google Scholar
• Brady MS, Lee F, Petrie H, Eckels DD, Lee JS. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 2000; 48:621 - 626
   PubMed Web of Science ®Google Scholar
• Curiel-Lewandrowski C, Demierre MF. Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol 2000; 43:167 - 185
   PubMed Web of Science ®Google Scholar
• Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003; 83:1555 - 1567
   PubMed Web of Science ®Google Scholar
• Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006; 66:3629 - 3638
   PubMed Web of Science ®Google Scholar
• Buckley KJ, Hayashi M. Lytic activity localized to membrane-spanning region of phi X174 E protein. Mol Gen Genet 1986; 204:120 - 125
   PubMedGoogle Scholar
• Maratea D, Young K, Young R. Deletion and fusion analysis of the phage phiX174 lysis gene E. Gene 1985; 40:39 - 46
   PubMed Web of Science ®Google Scholar
• Pfründer H, Amidjojo M, Kragl U, Weuster-Botz D. Efficient whole-cell biotransformation in a biphasic ionic liquid/water system. Angew Chem Int Ed 2004; 43:4529 - 4531
   PubMed Web of Science ®Google Scholar
• Pfründer H, Jones R, Weuster-Botz D. Water immiscible ionic liquids as solvents for whole cell biocatalysis. J Biotechnol 2006; 124:182 - 190
   PubMed Web of Science ®Google Scholar
• Yang Z, Pan W. Ionic liquids: Green solvents for nonaqueous biocatalysis. Enzyme and Microbial Technology 2005; 37:19 - 28
   Web of Science ®Google Scholar
• Kaftzik N, Wasserscheid P, Kragl U. Use of ionic liquids to increase the yield and enzyme stability in the β-galactosidase catalysed cynthesis of n-acetyllactosamine. Org Process Res Dev 2002; 6:553 - 557
   Web of Science ®Google Scholar